source
- Ionis shares tumble over $1 billion as Tryngolza sales forecast cut in halfIonis Pharmaceuticals saw its market value drop by more than $1 billion after it lowered its sales outlook for Tryngolza, a triglyceride‑lowering therapy. The company now expects $50 million in sa…
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.BioSpace · 1h ago↗ source
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence risk